The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188213 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Beatrice Foglia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Experimental Medicine and Clinical Pathology, Department of Clinical and Biological Sciences, University of Torino, Corso Raffaello 30, 10125…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Oncostatin M, Oncostatin M Receptor beta Subunit. Die Arbeit nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, AIRC.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the emerging leading cause of Chronic Liver Disease (CLD) worldwide, with a global prevalence of approximately 30% in the general population that parallels global rates of obesity and Type 2 Diabetes (T2D). Although two drugs (Resmetirom and Semaglutide) have been recently approved for clinical use, their ability to block or slow down disease progression to metabolic dysfunction-associated Steatohepatitis (MASH) and liver fibrosis is limited to a subset of patients, and no data are available at present for the efficacy of these drugs in compensated cirrhosis or in relation to hepatocellular carcinoma (HCC) development. Moreover, there is a lack of reliable biomarkers able to identify MASH patients at risk of disease progression and/or HCC development. In line with the knowledge that pro-inflammatory cytokines play a key role in MASLD/MASH progression and HCC development, in this review, we will discuss the role in this disease and other CLDs of Oncostatin M (OSM), a cytokine belonging to the IL6 family, and of pathways involving OSM and its receptor β (OSM/OSMRβ axis). OSM and related pathways are emerging as selective in sustaining disease progression by promoting chronic inflammation and fibrogenesis. The OSM/OSMRβ axis is proposed to be involved in MASH-related HCC development by affecting proliferation, angiogenesis, invasiveness and metastasis as well as by reshaping the MASH-related tumor immune microenvironment. OSM and the OSM/OSMRβ axis are emerging as a candidate biomarker and putative MASH-related therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Experimental Medicine and Clinical Pathology, Department of Clinical and Biological Sciences, University of Torino, Corso Raffaello 30, 10125 Torino, Italy.
ORCID-Profile: Beatrice Foglia, Stefania Cannito, Maurizio Parola
Förderung
- Italian Association for Cancer Research
- AIRC
Zitieren
APA
Foglia, B., Nurcis, J., Signorini, M., Novo, E., Bocca, C., Cannito, S., & Parola, M. (2026). The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188213
Vancouver
Foglia B, Nurcis J, Signorini M, Novo E, Bocca C, Cannito S, et al. The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188213
BibTeX
@article{Foglia2026,
author = {Foglia, Beatrice and Nurcis, Jessica and Signorini, Marta and Novo, Erica and Bocca, Claudia and Cannito, Stefania and Parola, Maurizio},
title = {The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188213}
}
EUVIMED